Connect with us

Featured

Premier Health Group Presenting New Opportunity For Health Technology

Joe Samuel

Published

on

CLICK HERE FOR AN UPDATED REPORT ON PREMIER HEALTH GROUP (PHGRF) (PHGI)

If you’re familiar with what Reliq Technologies has accomplished over the last year, you’re well aware that telemedicine and mHealth services, apps and platforms are increasingly gaining a foothold over traditional healthcare right now.

The rising use of mobile access points like smartphones and tablets to deliver innovative healthcare solutions to patients has helped push this growth. Some of the major factors driving the telemedicine market include increasing healthcare costs, growing aging population and the rising incidence rate of chronic diseases.

What Reliq has been able to do in such a short time with community-based healthcare and its iUGO Care platform emphasizes its dedication to offering high-quality care for patients. There’s a big “BUT” here…Reliq has done a great job at advancing healthcare technology, BUT their latest deal could be a real game changer; not only for Reliq but also for a newly trading public company on the cutting edge of telehealthcare.

Healthcare Technology Evolution Presenting New Potential For Investors

This quarter Reliq Health was selected by a company called Premier Health Group (PHGI.CN) (PHGRF) as the EXCLUSIVE technology partner for Premier’s HealthVue clinics and 100,000 active patients. What does this mean for Premier Health Group?

For starters, Reliq will be providing HelathVue with branded telemedicine, remote monitoring & artificial intelligence solutions for both the clinical staff and patients. This move essentially supercharges Premier Health Group to rapidly scale its platform, increase patient numbers and in turn, boost practice revenue.

health care technology

By using Reliq’s technology-back-end, Premier Health Group will be positioned to give patients the ability to do a TON of different things. Here’s just a small taste of what Premier Health Group will allow patients to do with its HealVue patient platform:

  1. Book appointments
  2. See their general practitioners or specialists
  3. Review patient info
  4. Talk in real time with clinicians or pharmacists
  5. Refill prescriptions
  6. Share health data collected within a patient’s own home with HealthVue’s care team

Think about the potential with a company like Premier Health Group right now; especially for countries like Canada where approximately 15% of Canadians aged 12 and older don’t have a primary care physician. Also keep in mind that nearly two-thirds (59%) of seniors are unable to get a same-or next-day appointment and almost 7 in 10 Canadians avoid seeing a doctor when they are sick.

Now, take into account that there is a shortage of primary care doctors and nurses, especially in remote and rural communities, leads to clinician burn out and patients frustrated by long wait times.

This type of solution could be an absolute game-changer within the healthcare space.

Industry Facts Show Strong Growth Ahead On Multiple Fronts

The healthcare sector is seeing a dynamic shift in what leads growth for this market. The “usual suspects” that include traditional drug therapies and FDA submissions are still very evident, but a newcomer has been added to the mix.

Healthcare technology has been boosting attention to healthcare stocks recently. The MarketsAndMarkets report “Healthcare IThealthcare technologyMarket by Product (EHR, RIS, PACS, VNA, CPOE, HIE, Telehealth, Healthcare Analytics, Population Health Management, Supply Chain Management, CRM, Fraud Management, Claims Management) End User (Provider, Payer) – Global Forecast to 2021″, shows that the healthcare IT market is projected to reach $280.25 Billion by 2021 from $134.25 Billion in 2016, at a CAGR of 15.9% during the forecast period.

Specific to the mobile market, according to research from Kalorama Information, the mobile health market could reach an impressive $86.6 billion by 2020, a yearly increase of 20.8% over a five-year period (1).

In the race to rethink patient care, many innovative companies are creating breakthrough solutions that give patients to the ability to receive medical care from the comfort of their homes. However, while technology is rapidly evolving, the stock market hasn’t caught up yet. Investors have limited access to stocks specifically involved with this industry.

Furthermore, Research And Markets reports (2) that the market for telemedicine was valued at $ 29.6 Billion in 2017 and is anticipated to grow at a compounded annual rate of approximately 19% during 2017-2022. The reported growth of the market is likely to be driven by increasing adoption of telemedicine, rising incidences of chronic diseases, growing geriatric population, government initiatives, and a shortage of physicians amongst others.

A New Opportunity For Healthcare & A New Opportunity For Investors

By utilizing the powerful technology offered by Reliq, Premier Health Group (PHGI.CN) (PHGRF) and its HealthVue platform appear positioned to provide a unique opportunity for capitalizing on the Canadian market. The lack of primary care physicians, the growing number of seniors unable to visit a physical location, and the inability to get a same or next day appointment are all factors that contribute to a perfect environment for telehealth technology to thrive.

Additionally, since it is government funded in BC, there’s no additional cost to the patient. This also extends to prescriptions, which can be electronically submitted to a pharmacy of choice or delivered free by a preferred pharmacy partner. Essentially, it allows users the ability to access their healthcare professionals, engage with doctors and even send monitoring data to doctors right from the palm of a patient’s hand, 24/7.

With countries like Canada presenting a more near-term opportunity to fill a deep void, telemedicine has the sound footing to take advantage of future trends. Premier Health Group (PHGI.CN) (PHGRF)‘s HealthVue could offer substantial value for both its patients and investors alike.

technology stock price


DISCLAIMER:  Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full disclaimer.

End Notes

1.) Kalorama Information: https://www.kaloramainformation.com/mhealth-Worldwide-9138421/?progid=88153&__hstc=183052025.7c5c237ee824c116b58ae8424b2ad343.1540402411968.1540402411968.1540402411968.1&__hssc=183052025.1.1540402411969&__hsfp=3707452877

2.) Research and Markets:https://www.researchandmarkets.com/reports/4536701/global-telemedicine-market-outlook-2018-2022

Continue Reading
Click to comment

Biotechnology

Biotech Stocks To Watch In June: Cara Therapeutics (CARA) & Intellia Therapeutics (NTLA)

Jon Phillip

Published

on

biotech stocks to watch june

Among biotech companies, the competition between Cara Therapeutics Inc (CARA) and Intellia Therapeutics Inc (NTLA) has been an intriguing one. The two companies had been on the same level as far as the market cap goes during most of the year so far.

But Cara has now pulled ahead by as much as $150 million following positive data from its lead product candidate. That being said, it is also important to keep in mind that if an investor is looking at a long term investment, then the disparity in market cap between the two companies is a minor. Here’s a look at the pros and cons of Cara and Intellia.

Cara Therapeutics (CARA)

Cara Therapeutics is currently on the rise. Its lead product candidate Korsuva injection delivered highly encouraging results in its Phase 3 trial. It’s now believed that it would not be long before Cara has its first product on the market.

[NEXT] Biotech Companies Are Driving Innovation…See Which Ones

It is meant for the treatment of moderate-to-severe chronic kidney disease-associated pruritus. According to reports, the results were great. Another late-stage test is going to be conducted soon. The results could be announced by the end of this year. If Korsuve is approved, then it will be marketed by Fresenius Medical Care and Vifor Pharma Group.

Cara has entered joint ventures with those companies to market the product in the United States, Japan, and South Korea. An oral version of Korsuva is also in the pipeline and could prove to be another important development.

Intellia Therapeutics (NTLA)

Intellia Therapeutics (INTA) is involved in creating CRISPR gene editing therapies. It is a segment that has a lot of promise in the future. Even though the company is some years away from having anything on the market, the promise of gene editing therapy is exciting. So much so that Intellia has already found partners in big-ticket firms like Regeneron and Novartis.

Intellia is expected to file for FDA approval for the clinical study into its lead product NLTA-2001 in 2020. It is meant for the treatment of transthyretin amyloidosis, an uncommon genetic disease. Studies into the products have proven to be promising so far. The company is also working on a product to treat myeloid leukemia.

Now when it comes to choosing between Cara and Intellia, experts believe that the former could a better company. It’s already on the verge of having an approved product on the market. Intellia, on the other hand, is likely to be some years away from winning approval.

Continue Reading

Featured

4 Security Penny Stocks To Watch

A. Lawrence

Published

on

As Threats Arise, Security Stocks Take Center Stage In 2019

With the Federal Reserve’s meeting coming, the general market is bracing for anything. Meanwhile, penny stocks are continuing to climb at absurd rates. Trading penny stocks as of late has brought many investors fruitful profits and they look to continue this trend. Here are some security penny stocks to watch for the remainder of June 2019:

Security Penny Stock #1
Liberty Defense Holdings (SCAN.V)
Market Cap: $46.404M

Liberty Defense Holdings Ltd. (SCAN.V) is a security company looking to take the industry into the next century. Liberty’s HEXWAVE product is a 3-dimensional scanning device that can detect weapons and threats of any kind. The product can do this both with speed and discretion ensuring privacy for citizens.

Liberty signed a Memorandum of Understanding with the soccer team FC Bayern München to beta test HEXWAVE in their arena. They join an ever-growing list of places that have signed MOU’s to beta test Liberty’s product. This MOU expands its ability to comply with and test the market requirements for their product internationally.

“The reception to our HEXWAVE product has been fantastic and we are excited about working alongside FC Bayern Munich, a team that is a household name in both Europe and North America, […] Our ability to deploy in both indoor and outdoor settings, with covert and overt applications, sets us apart and has also been driving increasing interest from the market.” 

Bill Riker, CEO of Liberty

Security Penny Stock #2
Magal Security Systems (MAGS)
Market Cap: $101.371M

Magal Security Systems Ltd. (MAGS) provides security solutions both online and physical. Some services provided include identifying potential security problems, integrating new systems, and custom designs for any type of security needs.

Recently, Magal received a $5.5 million contract for its advanced perimeter intrusion detection system. The system prevents people from illegally crossing border fences and walls.

Dror Sharon, CEO of Magal, stated, “Magal is a world leader in perimeter intrusion technologies. Our growing wins of orders such as this – providing sensors for active international borders, is due to the decades of experience that we have in providing systems that have more than proven themselves in-the-field.”


Security Penny Stock #3
Rekor Systems (REKR)
Market Cap: $27.502M

Rekor Systems Inc. (REKR) is a company that has developed surveillance technology to enhance public safety, banking, and traffic management. Primarily, the company takes their advanced software, which utilizes machine learning and upgrades IP cameras to the next level. This reduces the cost when collecting highway tolls and helps manage traffic congestion.

REKR stock chart

Throughout June, Rekor Systems has been gaining recognition and application across the US. On June 3rd Rekor obtained a contract to start deploying its Mobile LBR-2 vehicle recognition systems. After this deployment on the 3rd, the LPR-2 system North Carolina law enforcement placed an order. On June 12th, Colorado highway authorities chose Rekor’s cloud system called NUMERUS to read enhance their license plate reading.


Security Penny Stock #4
BIO-key International (BKYI)
Market Cap: $18.03M

BIO-key International Inc. (BKYI) is a security technologies company that is pushing past the limits of fingerprint scanning. BIO-key provides a plethora of finger scanning products that provide security for your computer, hard drive, and the government. They have a partnership with Microsoft to develop biometric sign-in for Windows 10.

The company recently announced that a foreign defense ministry ordered more BIO-key deployment for secure access to Microsoft applications.

“We were delighted that such a capable and prestigious technology team determined that BIO-key met their security and scalability requirements and have now made follow-on investments to grow their user base.  Defense Ministries are constant targets of cyber-attacks, and we are glad to help them step up authentication to the highest assurance with NIST-verified accuracy and FIPS compliance.”

Jim Sullivan, SVP of BIO

security stocks
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 04/15/2018 – 5/15/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter now extended through June 21, 2019. We were paid $350,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Continue Reading

Featured

Stock Price Pre Market Update – June 19, 2019

Joe Samuel

Published

on

Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks

Click For Full Article


How Tech Is Making Life Easier?

The Answer Is ONE CLICK Away


Healthcare Penny Stocks To Watch

See For Yourself


Is Palatin Technologies (PTN) A Penny Stock To Buy Or Sell?

You Decide, Click Here

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com